Meiji Seika Reviews Expansion Plans
Japanese drugmaker Meiji Seika is expanding its overseas operations withfive joint ventures, two in China and one each in Thailand, Indonesia and Spain, reports Pharma Japan, with the expectations that foreign sales will reach 25 billion yen ($209.3 million) compared with the current level of 13 billion yen.
Leading the growth will be Meiji's Meiact (cefditoren pivoxil), being developed locally in Europe and Asia and, the company said, selection of marketing affiliates for the product in Europe is almost complete. PJ also noted that Meiji's senior executive vice president Yutaka Ogawa said the company is establishing R&D affiliates to ensure new products; five products are now under codevelopment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze